Literature DB >> 34354151

Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.

Jingxin Liu1,2, Qiang Zheng1,3, Xiao Mu2, Yanfei Zuo2, Bo Xu2, Yan Jin1,3, Yue Wang1,3, Hua Tian4, Yongguo Yang4, Qianqian Xue1,3, Ziling Huang1,3, Lijun Chen1,3, Bin Gu2, Xianxu Hou5, Linlin Shen5,6, Yan Guo2, Yuan Li7,8.   

Abstract

Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manually counting the PD-L1 positive stained tumor cells is an obviously subjective and time-consuming process. In this paper, we developed a new computer aided Automated Tumor Proportion Scoring System (ATPSS) to determine the comparability of image analysis with pathologist scores. A three-stage process was performed using both image processing and deep learning techniques to mimic the actual diagnostic flow of the pathologists. We conducted a multi-reader multi-case study to evaluate the agreement between pathologists and ATPSS. Fifty-one surgically resected lung squamous cell carcinoma were prepared and stained using the Dako PD-L1 (22C3) assay, and six pathologists with different experience levels were involved in this study. The TPS predicted by the proposed model had high and statistically significant correlation with sub-specialty pathologists' scores with Mean Absolute Error (MAE) of 8.65 (95% confidence interval (CI): 6.42-10.90) and Pearson Correlation Coefficient (PCC) of 0.9436 ([Formula: see text]), and the performance on PD-L1 positive cases achieved by our method surpassed that of non-subspecialty and trainee pathologists. Those experimental results indicate that the proposed automated system can be a powerful tool to improve the PD-L1 TPS assessment of pathologists.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34354151     DOI: 10.1038/s41598-021-95372-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  2 in total

1.  Quantification of histochemical staining by color deconvolution.

Authors:  A C Ruifrok; D A Johnston
Journal:  Anal Quant Cytol Histol       Date:  2001-08       Impact factor: 0.302

2.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

  2 in total
  2 in total

1.  Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.

Authors:  Guoping Cheng; Fuchuang Zhang; Yishi Xing; Xingyi Hu; He Zhang; Shiting Chen; Mengdao Li; Chaolong Peng; Guangtai Ding; Dadong Zhang; Peilin Chen; Qingxin Xia; Meijuan Wu
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.

Authors:  Ahmad Alhesa; Heyam Awad; Sarah Bloukh; Mahmoud Al-Balas; Mohammed El-Sadoni; Duaa Qattan; Bilal Azab; Tareq Saleh
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.